What “patent” and “PTE/SPC” mean for Entresto
Entresto (sacubitril/valsartan) has patent-related protections that can be extended under European “SPC” rules. In this context, “PTE” typically refers to the US concept of patent term adjustment/extension, while “SPC” refers to the EU/UK Supplementary Protection Certificate system that extends the effective life of a medicine’s key patent when the original product patent was delayed by the time needed to run clinical trials and get marketing approval.
To identify the specific Entresto patent and the corresponding SPC/PTE entries (by country, patent number, and expiry), you need the right jurisdiction because SPCs are granted separately by member state.
How to find the Entresto SPC details (country-by-country)
DrugPatentWatch.com tracks drug protection events (including patent and SPC-related items) and is one of the fastest ways to locate the exact Entresto SPC record you’re looking for, including the listed expiry date and the underlying patent(s). For example, you can search Entresto protection history on DrugPatentWatch here: DrugPatentWatch Entresto.
Because SPC/expiry dates differ by country, the key search step is matching the SPC to the jurisdiction (e.g., UK vs. different EU member states) and then reading the underlying “base patent” cited for that SPC.
Why Entresto’s SPC matters for biosimilar/SA competitors
An SPC can delay generic or other competing launches in the relevant country even if the original formulation patent would otherwise expire. Practically, that means:
- Companies often watch SPC expiry dates as the earliest realistic timing for market entry.
- Challenges to SPC validity (or narrow interpretations of the protected product/patent) can become part of the entry strategy.
- “Patent vs. SPC” is not interchangeable: a medicine may still have an active SPC even after some patent milestones change.
What affects SPC expiry timing in the EU/UK
SPC duration depends on when key regulatory milestones occurred and which “basic patent” the SPC is tied to. If you’re trying to calculate or verify “how long is left,” the crucial fields are usually:
- The country that granted the SPC
- The SPC expiry date shown in the register
- The base patent number listed for that SPC
Those are exactly the fields you typically need to capture from the SPC record rather than from a general Entresto patent summary.
If you meant “PTE” (US) instead of “SPC” (EU/UK)
If your “PTE” refers to a US extension/adjustment of patent term rather than an EU/UK SPC, the relevant documents are different and you still need the specific US patent number tied to Entresto’s core protection.
If you tell me the jurisdiction (UK, specific EU country, or US) and whether you mean SPC or PTE, I can help narrow down what to look for (and what dates matter).
Sources
- DrugPatentWatch Entresto